Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Boris Nowotny"'
Autor:
Maria Geis, Boris Nowotny, Marc-Dominic Bohn, Dina Kouhestani, Hermann Einsele, Thomas Bumm, Gernot Stuhler
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-6 (2021)
Geis et al. investigate the potential application of hemibodies, a pair of complementary antibody fragments that redirect T cells against cancer-defining antigen combinations, such as CD38 and SLAMF7, to target multiple myeloma. Their study provides
Externí odkaz:
https://doaj.org/article/3ee919498c4342e29413bd80927b94df
Autor:
Agnes Banaszek, Thomas G. P. Bumm, Boris Nowotny, Maria Geis, Kim Jacob, Matthias Wölfl, Johannes Trebing, Kirstin Kucka, Dina Kouhestani, Tea Gogishvili, Bastian Krenz, Justina Lutz, Leo Rasche, Dirk Hönemann, Hannes Neuweiler, Julia C. Heiby, Ralf C. Bargou, Harald Wajant, Hermann Einsele, Gert Riethmüller, Gernot Stuhler
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
The restriction of appropriate tumour-specific antigens is a current limitation for T cell-engaging immunotherapy. Here, the authors have designed a new system constituted by two halve antibodies, which engage T cells once binding to two different an
Externí odkaz:
https://doaj.org/article/2c0baf0c95d243a58f06fcb336d652c2
Autor:
Ralf C. Bargou, Gert Riethmüller, Kim Jacob, Matthias Wölfl, Thomas Bumm, Gernot Stuhler, Hermann Einsele, Maria Geis, Dina Kouhestani, Julia C. Heiby, Leo Rasche, Johannes Trebing, Tea Gogishvili, Boris Nowotny, Justina Lutz, Harald Wajant, Dirk Hönemann, Bastian Krenz, Hannes Neuweiler, Kirstin Kucka, Agnes Banaszek
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
Nature Communications
Nature Communications
T cell-engaging immunotherapies are changing the landscape of current cancer care. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. Here, we report on a T cell-engaging antibody derivative that comes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b418ff6f6b9473f3d0d0f1d2b09a16ec
https://doaj.org/article/2c0baf0c95d243a58f06fcb336d652c2
https://doaj.org/article/2c0baf0c95d243a58f06fcb336d652c2
Autor:
Tanja Schirmeister, Gabriele Pradel, Marc W. Kirschner, Axel Rethwilm, Thomas Schneider, Boris Nowotny
Publikováno v:
Antimicrobial agents and chemotherapy. 54(1)
Inhibition of the interaction of the human cytidine-deaminase APOBEC3G (A3G) with the human immunodeficiency virus (HIV) type 1-specific viral infectivity factor (Vif) represents a novel therapeutic approach in which a cellular factor with potent ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96a0c82cc12be3fd62436006c9a23c8
https://pubmed.ncbi.nlm.nih.gov/19841153
https://pubmed.ncbi.nlm.nih.gov/19841153